Aquinox Pharma pulls in $15M for cancer and inflammation

Aquinox Pharmaceuticals, a Vancouver drug developer, raised $14.5 million in a first funding round. Ventures West Capital led the round, joined by Johnson & Johnson Development Corp., Baker Brothers Investments and BC Advantage Funds.

Aquinox is developing drugs that inhibit a newly discovered enzyme called SHIP (for more detail, see here) that appears to play an important role in blood cancers and inflammatory diseases. The company’s lead drug candidate, AQX-MN100, is still in animal testing.

Next Story:
Previous Story:

Tags: ,

Photo of David P. Hamilton

About the Author,

David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.

blog comments powered by Disqus